XML 126 R43.htm IDEA: XBRL DOCUMENT v3.20.4
Associated companies (Tables)
 12 Months Ended
Dec. 31, 2020
Statement [line items]  
Schedule disclosing information related to associates
Net income statement effect
Other comprehensive income effect
Total comprehensive income effect
(USD millions)
2020
2019
2018
2020
2019
2018 1
2020
2019
2018
Roche Holding AG, Switzerland
677
662
526
– 56
– 94
75
621
568
601
GlaxoSmithKline Consumer

Healthcare Holdings Ltd., UK






5 910






– 557






5 353
Others
– 4
– 3
2
– 4
– 3
2
Associated companies related to continuing operations
673
659
6 438
– 56
– 94
– 482
617
565
5 956
 1  In 2018, Novartis share of other comprehensive income recognized by associated companies, net of taxes of USD 511 million was recycled into the consolidated income statement as a result of the divestment of the investment in GSK Consumer Healthcare Holdings Ltd. No Novartis share of other comprehensive income recognized by associated companies, net of taxes was recycled into the consolidated income statement in 2020 and 2019.
Schedule disclosing information related to associates, balance sheet value
Balance sheet value


(USD millions)
December 31,

2020
December 31,

2019
Roche Holding AG, Switzerland
9 407
8 445
Others
225
199
Total
9 632
8 644
Roche Holding AG, Switzerland  
Statement [line items]  
Associates summarized financial information


(CHF billions)


Current assets
Non-current

assets
Current

liabilities
Non-current

liabilities
December 31, 2019
31.3
56.4
24.1
23.1
June 30, 2020
27.7
55.7
22.5
23.1


(CHF billions)




Revenue




Net income
Other

comprehen-

sive income
Total

comprehen-

sive income
December 31, 2019
63.8
12.3
– 0.9
11.4
June 30, 2020
30.4
7.2
– 0.7
6.5
Purchase price allocation associates


(USD millions)
December 31,

2020
Novartis share of Roche’s estimated net assets
2 585
Novartis share of reappraised intangible assets
117
Implicit Novartis goodwill
3 233
Current value of share in net identifiable assets

and goodwill


5 935
Accumulated equity accounting adjustments and translation effects less dividends received
3 472
Balance sheet value
9 407
Schedule disclosing information related to associates, net income effect
(USD millions)
2020
2019
2018
Novartis share of Roche's

estimated current-year

consolidated net income




913




910




799
Prior-year adjustment
– 64
– 129
– 125
Amortization of fair value

adjustments relating to

intangible assets, net of taxes

of USD 26 million (2019: USD 24

million; 2018: USD 40 million)








– 172








– 162








– 148
Partial release of deferred tax liability recognized
43
Net income effect
677
662
526
GlaxoSmithKline Consumer Healthcare Holdings Ltd., UK  
Statement [line items]  
Schedule disclosing information related to associates, net income effect
(USD millions)
2018
Novartis share of

GSK Consumer Healthcare's

estimated current-year

consolidated net income






119
Prior-year adjustment
4
Amortization of fair value

adjustments relating to

intangible assets and inventory,

net of taxes of USD 1 million






– 3
Pre-tax gain on divestment of GSK Consumer Healthcare
5 790
Net income effect
5 910